Gastrointestinal cancers (including colon, stomach, liver and pancreatic cancer) and gynecological cancers (including ovarian, endometrial and cervical cancer) are common types of solid malignancies worldwide. The cancer cell resistance to anti-cancer treatments (chemotherapy, radiotherapy and targeted therapies) can occur due to many different mechanisms, including specific genetic and epigenetic changes in the cancer cell and tumor microenvironment that help cancer cells to reside. To develop new strategies to overcome intrinsic and acquired resistance that limit the effectiveness of anti-cancer therapies, clarification of the underlying molecular mechanisms affecting therapeutic responses in gastrointestinal and gynecological cancers is urgently needed.
Non-coding RNAs, including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), make up most of the human transcriptome and have been hot spots in recent years. Accumulating evidence indicates that miRNAs, lncRNAs and circRNAs play crucial roles in tumorigenesis, tumor development, metastasis and sensitivity to radiation, chemotherapy and targeted therapies.
This Research Topic provides timely, computational and experimental insights into the therapeutic resistance mechanisms regulated by non-coding RNAs in human cancers (especially gastrointestinal and gynecological cancers).
We welcome original research articles and reviews that explore, but are not limited to, the following list of themes:
• Novel non-coding RNAs predicting response or resistance to anti-cancer drugs.
• New epigenetic mechanisms regulating epithelial-to-mesenchymal transition (EMT), cancer stemness, angiogenesis,
immune evasion and inflammation.
• Cross-talk between miRNAs, lncRNAs and circRNAs as a molecular basis for cancer therapy resistance.
• Developing non-coding RNAs-based therapeutics.
• New technologies for epigenetic study on cancer biology and therapy resistance.
Please note: The findings based on omics data integration should be also supported by observational/experimental data. Descriptive studies and studies consisting only of bioinformatic investigation of accessible genomic or transcriptomic data do not fall within the scope of the journal.
Gastrointestinal cancers (including colon, stomach, liver and pancreatic cancer) and gynecological cancers (including ovarian, endometrial and cervical cancer) are common types of solid malignancies worldwide. The cancer cell resistance to anti-cancer treatments (chemotherapy, radiotherapy and targeted therapies) can occur due to many different mechanisms, including specific genetic and epigenetic changes in the cancer cell and tumor microenvironment that help cancer cells to reside. To develop new strategies to overcome intrinsic and acquired resistance that limit the effectiveness of anti-cancer therapies, clarification of the underlying molecular mechanisms affecting therapeutic responses in gastrointestinal and gynecological cancers is urgently needed.
Non-coding RNAs, including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), make up most of the human transcriptome and have been hot spots in recent years. Accumulating evidence indicates that miRNAs, lncRNAs and circRNAs play crucial roles in tumorigenesis, tumor development, metastasis and sensitivity to radiation, chemotherapy and targeted therapies.
This Research Topic provides timely, computational and experimental insights into the therapeutic resistance mechanisms regulated by non-coding RNAs in human cancers (especially gastrointestinal and gynecological cancers).
We welcome original research articles and reviews that explore, but are not limited to, the following list of themes:
• Novel non-coding RNAs predicting response or resistance to anti-cancer drugs.
• New epigenetic mechanisms regulating epithelial-to-mesenchymal transition (EMT), cancer stemness, angiogenesis,
immune evasion and inflammation.
• Cross-talk between miRNAs, lncRNAs and circRNAs as a molecular basis for cancer therapy resistance.
• Developing non-coding RNAs-based therapeutics.
• New technologies for epigenetic study on cancer biology and therapy resistance.
Please note: The findings based on omics data integration should be also supported by observational/experimental data. Descriptive studies and studies consisting only of bioinformatic investigation of accessible genomic or transcriptomic data do not fall within the scope of the journal.
